RESUMEN
We prepared a polyclonal antibody against a teicoplanin (TEIC)-bovine serum albumin conjugate that was specific to both conjugated and free forms of TEIC. We demonstrated that this antibody could be used to detect the time-dependent localization of TEIC in rat kidneys. Immunohistochemistry revealed immunoreactivity specifically in the microvilli and apical cytoplasm of epithelial cells in proximal tubule segments S1 and S2, 1 h after intravenous TEIC injection, with higher staining intensity in the S2 segments. The epithelial cells of S3 segments showed moderate immunostaining with a few cells exhibiting nuclear staining. Furthermore, we found that the distal tubules and collecting ducts contained both TEIC-positive and -negative cells. TEIC immunoreactivity decreased rapidly over time; only weak staining remained in the S3 segments, distal tubules, and collecting ducts 24 h after administration. No staining was detected 7 days after injection. These results were significantly different from those of our previous study obtained using vancomycin, which showed moderate staining in the proximal tubule segments S1 and S2, distal tubules, and the collecting ducts 8 days after administration. The lower TEIC accumulation in tissues may account for a lower risk of adverse events compared to that using vancomycin.
Asunto(s)
Anticuerpos , Inmunohistoquímica/métodos , Riñón/metabolismo , Teicoplanina/análisis , Teicoplanina/farmacocinética , Animales , Antibacterianos , Inyecciones Intravenosas , Ratas , Teicoplanina/administración & dosificación , Teicoplanina/inmunologíaAsunto(s)
Alérgenos/efectos adversos , Antibacterianos/efectos adversos , Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad Tardía/diagnóstico , Hipersensibilidad Inmediata/diagnóstico , Teicoplanina/efectos adversos , Adulto , Anciano , Anciano de 80 o más Años , Alérgenos/inmunología , Antibacterianos/inmunología , Femenino , Humanos , Pruebas Intradérmicas , Masculino , Persona de Mediana Edad , Teicoplanina/inmunología , Adulto JovenAsunto(s)
Pustulosis Exantematosa Generalizada Aguda/diagnóstico , Antibacterianos/efectos adversos , Artroplastia de Reemplazo de Rodilla , Hipersensibilidad a las Drogas/diagnóstico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/diagnóstico , Piel/patología , Teicoplanina/efectos adversos , Pustulosis Exantematosa Generalizada Aguda/etiología , Alérgenos/inmunología , Antibacterianos/uso terapéutico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/etiología , Femenino , Humanos , Persona de Mediana Edad , Pruebas del Parche , Teicoplanina/inmunología , Teicoplanina/uso terapéuticoRESUMEN
There are only a few reports of thrombocytopenia associated with clinical doses of teicoplanin, a glycopeptide antibiotic used against Gram-positive bacteria. We investigated 39 patients receiving teicoplanin; 31 were thrombocytopenic with platelet counts between 1-105 x 10(9)/l and 8 were not thrombocytopenic. We identified 14 thrombocytopenic cases (45%) and two (25%) non-thrombocytopenic cases with IgG teicoplanin-dependent platelet-reactive antibodies. Use of glycoprotein (GP) capture enzyme-linked immunosorbent assay with platelets and GPIIb/IIIa transfected Chinese Hamster Ovary cells as well as flow cytometry with GP-deficient platelets indicated that the GPIIb/IIIa complex is a major target antigen of these antibodies.
Asunto(s)
Antibacterianos/inmunología , Anticuerpos/sangre , Teicoplanina/inmunología , Trombocitopenia/inducido químicamente , Animales , Reacciones Antígeno-Anticuerpo , Plaquetas/inmunología , Células CHO , Cricetinae , Ensayo de Inmunoadsorción Enzimática/métodos , Citometría de Flujo , Técnica del Anticuerpo Fluorescente Indirecta , Humanos , Inmunoglobulina G/sangre , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/inmunologíaRESUMEN
To test the role of bacterial fractions released from intestinal flora during immunomodulation by antimicrobial agents, BALB/c mice were treated with the non-absorbable antibiotics polymyxin B or teicoplanin by the intragastric route. The composition of faecal microbiota and the capacity of spleen cells to proliferate in response to B-cell and T-cell mitogens were assessed at several times during the treatment. Both antibiotics lowered the count of some bacteria of the intestinal flora and induced significant modifications in spleen cell ability to proliferate in response to mitogens. Thus, the active fractions released from intestinal bacteria during antibiotic treatments may be able to induce immunomodulating effects.